Nine Psychiatric Medications Approved Since 2011
The nine psychiatric medications that have received first-time U.S. FDA approval since 2011 include a mix of novel agents and new formulations, though the evidence shows limited true innovation in this period.
The Nine New Psychiatric Medications Are:
Based on the most recent comprehensive analysis 1, 2, 3, the following medications represent first-time approvals:
Novel Antipsychotics (4 medications):
- Cariprazine - D3-preferring dopamine partial agonist for schizophrenia and bipolar disorder 3
- Brexpiprazole - Dopamine partial agonist with serotonergic activity 3
- Lumateperone - Modulates dopamine, serotonin, and glutamate systems 3
- Pimavanserin - Selective 5-HT2A inverse agonist for Parkinson's disease psychosis 3
Antidepressants with Novel Mechanisms (3 medications):
- Esketamine (intranasal) - NMDA receptor antagonist for treatment-resistant depression and acute suicidal ideation 4, 2
- Brexanolone (IV) - GABA-A receptor modulator for postpartum depression 4
- Zuranolone (oral) - GABA-A receptor modulator for postpartum depression 4
Combination Products (2 medications):
- Olanzapine/samidorphan (OLZ/SAM) - Combines antipsychotic with opioid antagonist to mitigate weight gain 4, 3
- Dextromethorphan/bupropion - NMDA antagonist combined with CYP2D6 inhibitor for major depressive disorder 4
Key Context About Innovation
The degree of innovation has been limited. Of the 22 new psychiatric drugs and supplemental indications identified between 2012-2024, only 7 (31.8%) were categorized as "first-in-class," while 13 (59.1%) were merely "addition-to-class" 1. This represents significant stagnation compared to other medical specialties.
Important Caveats:
- No new medications were approved for anxiety disorders, PTSD, or OCD during this period 5
- Most approvals represent new delivery methods (subcutaneous risperidone, transdermal asenapine, inhaled loxapine) rather than novel therapeutic approaches 3
- Only 3 medications (13.6%) received FDA priority review status 1
- None were included on the WHO's Model List of Essential Medicines 1
The recently approved xanomeline/trospium (KarXT) in 2024 represents the first non-dopaminergic antipsychotic, targeting M1/M4 muscarinic receptors 6, marking a potential shift after 70 years of dopamine-focused treatments.